Cargando…

No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study

BACKGROUND: Currently, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread globally, causing an unprecedented pandemic. However, there is no specific antiviral therapy for coronavirus disease 2019 (COVID-19). We conducted a clinical trial to compare the effectiveness of three ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yin-Qiu, Tang, Sheng-Quan, Xu, Xiao-Lei, Zeng, Yan-Ming, He, Xiao-Qing, Li, Yao, Harypursat, Vijay, Lu, Yan-Qiu, Wan, Yan, Zhang, Lu, Sun, Qiang-Zhong, Sun, Nan-Nan, Wang, Gui-Xue, Yang, Zhong-Ping, Chen, Yao-Kai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378850/
https://www.ncbi.nlm.nih.gov/pubmed/32765274
http://dx.doi.org/10.3389/fphar.2020.01071
_version_ 1783562513352228864
author Huang, Yin-Qiu
Tang, Sheng-Quan
Xu, Xiao-Lei
Zeng, Yan-Ming
He, Xiao-Qing
Li, Yao
Harypursat, Vijay
Lu, Yan-Qiu
Wan, Yan
Zhang, Lu
Sun, Qiang-Zhong
Sun, Nan-Nan
Wang, Gui-Xue
Yang, Zhong-Ping
Chen, Yao-Kai
author_facet Huang, Yin-Qiu
Tang, Sheng-Quan
Xu, Xiao-Lei
Zeng, Yan-Ming
He, Xiao-Qing
Li, Yao
Harypursat, Vijay
Lu, Yan-Qiu
Wan, Yan
Zhang, Lu
Sun, Qiang-Zhong
Sun, Nan-Nan
Wang, Gui-Xue
Yang, Zhong-Ping
Chen, Yao-Kai
author_sort Huang, Yin-Qiu
collection PubMed
description BACKGROUND: Currently, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread globally, causing an unprecedented pandemic. However, there is no specific antiviral therapy for coronavirus disease 2019 (COVID-19). We conducted a clinical trial to compare the effectiveness of three antiviral treatment regimens in patients with mild to moderate COVID-19. METHODS: This was a single-center, randomized, open-labeled, prospective clinical trial. Eligible patients with mild to moderate COVID-19 were randomized into three groups: ribavirin (RBV) plus interferon-α (IFN-α), lopinavir/ritonavir (LPV/r) plus IFN-α, and RBV plus LPV/r plus IFN-α at a 1:1:1 ratio. Each patient was invited to participate in a 28-d follow-up after initiation of an antiviral regimen. The outcomes include the difference in median interval to SARS-CoV-2 nucleic acid negativity, the proportion of patients with SARS-CoV-2 nucleic acid negativity at day 14, the mortality at day 28, the proportion of patients re-classified as severe cases, and adverse events during the study period. RESULTS: In total, we enrolled 101 patients in this study. Baseline clinical and laboratory characteristics of patients were comparable among the three groups. In the analysis of intention-to-treat data, the median interval from baseline to SARS-CoV-2 nucleic acid negativity was 12 d in the LPV/r+IFN-α-treated group, as compared with 13 and 15 d in the RBV+IFN-α-treated group and in the RBV+LPV/r+ IFN-α-treated group, respectively (p=0.23). The proportion of patients with SARS-CoV-2 nucleic acid negativity in the LPV/r+IFN-α-treated group (61.1%) was higher than the RBV+ IFN-α-treated group (51.5%) and the RBV+LPV/r+IFN-α-treated group (46.9%) at day 14; however, the difference between these groups was calculated to be statistically insignificant. The RBV+LPV/r+IFN-α-treated group developed a significantly higher incidence of gastrointestinal adverse events than the LPV/r+ IFN-α-treated group and the RBV+ IFN-α-treated group. CONCLUSIONS: Our results indicate that there are no significant differences among the three regimens in terms of antiviral effectiveness in patients with mild to moderate COVID-19. Furthermore, the combination of RBV and LPV/r is associated with a significant increase in gastrointestinal adverse events, suggesting that RBV and LPV/r should not be co-administered to COVID-19 patients simultaneously. CLINICAL TRIAL REGISTRATION: www.ClinicalTrials.gov, ID: ChiCTR2000029387. Registered on January 28, 2019.
format Online
Article
Text
id pubmed-7378850
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-73788502020-08-05 No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study Huang, Yin-Qiu Tang, Sheng-Quan Xu, Xiao-Lei Zeng, Yan-Ming He, Xiao-Qing Li, Yao Harypursat, Vijay Lu, Yan-Qiu Wan, Yan Zhang, Lu Sun, Qiang-Zhong Sun, Nan-Nan Wang, Gui-Xue Yang, Zhong-Ping Chen, Yao-Kai Front Pharmacol Pharmacology BACKGROUND: Currently, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread globally, causing an unprecedented pandemic. However, there is no specific antiviral therapy for coronavirus disease 2019 (COVID-19). We conducted a clinical trial to compare the effectiveness of three antiviral treatment regimens in patients with mild to moderate COVID-19. METHODS: This was a single-center, randomized, open-labeled, prospective clinical trial. Eligible patients with mild to moderate COVID-19 were randomized into three groups: ribavirin (RBV) plus interferon-α (IFN-α), lopinavir/ritonavir (LPV/r) plus IFN-α, and RBV plus LPV/r plus IFN-α at a 1:1:1 ratio. Each patient was invited to participate in a 28-d follow-up after initiation of an antiviral regimen. The outcomes include the difference in median interval to SARS-CoV-2 nucleic acid negativity, the proportion of patients with SARS-CoV-2 nucleic acid negativity at day 14, the mortality at day 28, the proportion of patients re-classified as severe cases, and adverse events during the study period. RESULTS: In total, we enrolled 101 patients in this study. Baseline clinical and laboratory characteristics of patients were comparable among the three groups. In the analysis of intention-to-treat data, the median interval from baseline to SARS-CoV-2 nucleic acid negativity was 12 d in the LPV/r+IFN-α-treated group, as compared with 13 and 15 d in the RBV+IFN-α-treated group and in the RBV+LPV/r+ IFN-α-treated group, respectively (p=0.23). The proportion of patients with SARS-CoV-2 nucleic acid negativity in the LPV/r+IFN-α-treated group (61.1%) was higher than the RBV+ IFN-α-treated group (51.5%) and the RBV+LPV/r+IFN-α-treated group (46.9%) at day 14; however, the difference between these groups was calculated to be statistically insignificant. The RBV+LPV/r+IFN-α-treated group developed a significantly higher incidence of gastrointestinal adverse events than the LPV/r+ IFN-α-treated group and the RBV+ IFN-α-treated group. CONCLUSIONS: Our results indicate that there are no significant differences among the three regimens in terms of antiviral effectiveness in patients with mild to moderate COVID-19. Furthermore, the combination of RBV and LPV/r is associated with a significant increase in gastrointestinal adverse events, suggesting that RBV and LPV/r should not be co-administered to COVID-19 patients simultaneously. CLINICAL TRIAL REGISTRATION: www.ClinicalTrials.gov, ID: ChiCTR2000029387. Registered on January 28, 2019. Frontiers Media S.A. 2020-07-14 /pmc/articles/PMC7378850/ /pubmed/32765274 http://dx.doi.org/10.3389/fphar.2020.01071 Text en Copyright © 2020 Huang, Tang, Xu, Zeng, He, Li, Harypursat, Lu, Wan, Zhang, Sun, Sun, Wang, Yang and Chen http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Huang, Yin-Qiu
Tang, Sheng-Quan
Xu, Xiao-Lei
Zeng, Yan-Ming
He, Xiao-Qing
Li, Yao
Harypursat, Vijay
Lu, Yan-Qiu
Wan, Yan
Zhang, Lu
Sun, Qiang-Zhong
Sun, Nan-Nan
Wang, Gui-Xue
Yang, Zhong-Ping
Chen, Yao-Kai
No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study
title No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study
title_full No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study
title_fullStr No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study
title_full_unstemmed No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study
title_short No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study
title_sort no statistically apparent difference in antiviral effectiveness observed among ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate coronavirus disease 2019: results of a randomized, open-labeled prospective study
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378850/
https://www.ncbi.nlm.nih.gov/pubmed/32765274
http://dx.doi.org/10.3389/fphar.2020.01071
work_keys_str_mv AT huangyinqiu nostatisticallyapparentdifferenceinantiviraleffectivenessobservedamongribavirinplusinterferonalphalopinavirritonavirplusinterferonalphaandribavirinpluslopinavirritonavirplusinterferonalphainpatientswithmildtomoderatecoronavirusdisease2019resultsofarandomi
AT tangshengquan nostatisticallyapparentdifferenceinantiviraleffectivenessobservedamongribavirinplusinterferonalphalopinavirritonavirplusinterferonalphaandribavirinpluslopinavirritonavirplusinterferonalphainpatientswithmildtomoderatecoronavirusdisease2019resultsofarandomi
AT xuxiaolei nostatisticallyapparentdifferenceinantiviraleffectivenessobservedamongribavirinplusinterferonalphalopinavirritonavirplusinterferonalphaandribavirinpluslopinavirritonavirplusinterferonalphainpatientswithmildtomoderatecoronavirusdisease2019resultsofarandomi
AT zengyanming nostatisticallyapparentdifferenceinantiviraleffectivenessobservedamongribavirinplusinterferonalphalopinavirritonavirplusinterferonalphaandribavirinpluslopinavirritonavirplusinterferonalphainpatientswithmildtomoderatecoronavirusdisease2019resultsofarandomi
AT hexiaoqing nostatisticallyapparentdifferenceinantiviraleffectivenessobservedamongribavirinplusinterferonalphalopinavirritonavirplusinterferonalphaandribavirinpluslopinavirritonavirplusinterferonalphainpatientswithmildtomoderatecoronavirusdisease2019resultsofarandomi
AT liyao nostatisticallyapparentdifferenceinantiviraleffectivenessobservedamongribavirinplusinterferonalphalopinavirritonavirplusinterferonalphaandribavirinpluslopinavirritonavirplusinterferonalphainpatientswithmildtomoderatecoronavirusdisease2019resultsofarandomi
AT harypursatvijay nostatisticallyapparentdifferenceinantiviraleffectivenessobservedamongribavirinplusinterferonalphalopinavirritonavirplusinterferonalphaandribavirinpluslopinavirritonavirplusinterferonalphainpatientswithmildtomoderatecoronavirusdisease2019resultsofarandomi
AT luyanqiu nostatisticallyapparentdifferenceinantiviraleffectivenessobservedamongribavirinplusinterferonalphalopinavirritonavirplusinterferonalphaandribavirinpluslopinavirritonavirplusinterferonalphainpatientswithmildtomoderatecoronavirusdisease2019resultsofarandomi
AT wanyan nostatisticallyapparentdifferenceinantiviraleffectivenessobservedamongribavirinplusinterferonalphalopinavirritonavirplusinterferonalphaandribavirinpluslopinavirritonavirplusinterferonalphainpatientswithmildtomoderatecoronavirusdisease2019resultsofarandomi
AT zhanglu nostatisticallyapparentdifferenceinantiviraleffectivenessobservedamongribavirinplusinterferonalphalopinavirritonavirplusinterferonalphaandribavirinpluslopinavirritonavirplusinterferonalphainpatientswithmildtomoderatecoronavirusdisease2019resultsofarandomi
AT sunqiangzhong nostatisticallyapparentdifferenceinantiviraleffectivenessobservedamongribavirinplusinterferonalphalopinavirritonavirplusinterferonalphaandribavirinpluslopinavirritonavirplusinterferonalphainpatientswithmildtomoderatecoronavirusdisease2019resultsofarandomi
AT sunnannan nostatisticallyapparentdifferenceinantiviraleffectivenessobservedamongribavirinplusinterferonalphalopinavirritonavirplusinterferonalphaandribavirinpluslopinavirritonavirplusinterferonalphainpatientswithmildtomoderatecoronavirusdisease2019resultsofarandomi
AT wangguixue nostatisticallyapparentdifferenceinantiviraleffectivenessobservedamongribavirinplusinterferonalphalopinavirritonavirplusinterferonalphaandribavirinpluslopinavirritonavirplusinterferonalphainpatientswithmildtomoderatecoronavirusdisease2019resultsofarandomi
AT yangzhongping nostatisticallyapparentdifferenceinantiviraleffectivenessobservedamongribavirinplusinterferonalphalopinavirritonavirplusinterferonalphaandribavirinpluslopinavirritonavirplusinterferonalphainpatientswithmildtomoderatecoronavirusdisease2019resultsofarandomi
AT chenyaokai nostatisticallyapparentdifferenceinantiviraleffectivenessobservedamongribavirinplusinterferonalphalopinavirritonavirplusinterferonalphaandribavirinpluslopinavirritonavirplusinterferonalphainpatientswithmildtomoderatecoronavirusdisease2019resultsofarandomi